Baird analyst Eric Coldwell lowered the firm’s price target on Owens & Minor to $14 from $19 and keeps a Neutral rating on the shares. The firm said 3Q was largely in line with few surprises and the initial stock selloff seemed overdone. 4Q to be challenged by hurricane knock-on effects in PHS, partially offset by stronger Patient Direct, while CF expected to improve sequentially.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMI: